Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.34 |
| ▸ | CDK1 | P06493 | 5/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.34 |
| ▸ | GSK3A | P49840 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10740734 | 0.72 | PDE5A (0.65) | METAP2METAP1CCNB2CDK1CCNB1 | |
| SCHEMBL6012369 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1DAOCCNB2 | |
| SCHEMBL30615128 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1DAOCCNB2 | |
| SCHEMBL4719448 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1 | |
| Zarzissine SCHEMBL1514280 | 0.71 | NUDT1 (0.50) | METAP2METAP1EGLN1CDK5CDK5R1 | |
| SCHEMBL813686 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1CCNB2CDK1 | |
| SCHEMBL14409054 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1NUDT1 | |
| SCHEMBL29433971 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1NUDT1 | |
| SCHEMBL10611243 | 0.71 | METAP2 (0.44) | METAP2METAP1EGLN1DAOCCNB2 | |
| SCHEMBL4353284 | 0.71 | DAO (0.44) | DAOCCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| EP-2925319-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | University Of Rochester (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2836590-A2 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | Cytokinetics, Incorporated (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | CYTOKINETICS, INCORPORATED | 2014-10-09 | — | — | US | disclosed |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | CYTOKINETICS, INCORPORATED | 2014-10-09 | — | — | US | disclosed |
| WO-2014085795-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIVERSITY OF ROCHESTER (US) | 2014-06-05 | — | — | WO | disclosed |
| US-8716291-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716291-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2013155262-A2 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | CYTOKINETICS, INC (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130053389-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-7956056-B2 | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | disclosed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| US-5306819-A | Anxiolytic agents | NEUROGEN CORPORATION (US) | 1994-04-26 | — | — | US | disclosed |
| US-5306819-A | Anxiolytic agents | NEUROGEN CORPORATION (US) | 1994-04-26 | — | — | US | disclosed |
| WO-1994005665-A1 | CERTAIN ARYL AND CYCLOALKYL FUSED IMIDAZOPYRAZINOLS; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | METAP2 3693/4885METAP1 3592/4885EGLN1 3528/4885 |
| US-20130053389-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNI3, TNNT2, TNNC1 | METAP2 829/4885METAP1 1110/4885EGLN1 4593/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | METAP2 3693/4885METAP1 3592/4885EGLN1 3528/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | METAP2 4086/4885METAP1 4026/4885EGLN1 1858/4885 |
| US-20140303366-A1 | Certain 1H-Imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-Imidazo[4,5-b]pyrazin-2-ols and Methods for Their Use | TNNI3, TNNT2, TNNC1 | METAP2 510/4885METAP1 564/4885EGLN1 3672/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | METAP2 3693/4885METAP1 3592/4885EGLN1 3528/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | METAP2 829/4885METAP1 1110/4885EGLN1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.